SCHEMBL3299394

SCHEMBL3299394

CC(C)n1cnc2c(NC3CCC3)nc(F)nc21

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 12/20 0.61
CDK9 P50750 4/20 0.61
CDK1 P06493 3/20 0.58
CCNE1 P24864 8/20 0.46
CCNB1 P14635 1/20 0.46
CCNE2 O96020 7/20 0.46
CCNA2 P20248 6/20 0.46
CCNA1 P78396 6/20 0.46
FLT3 P36888 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
PKM P14618 1/20 0.44
NFKB1 P19838 1/20 0.44
ADORA1 P30542 1/20 0.44
THPO P40225 1/20 0.44
PMP22 Q01453 1/20 0.44
CCNT1 O60563 1/20 0.43
CCNT2 O60583 1/20 0.43
CLK1 P49759 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3306974 0.95 CDK2 (0.60) CDK2CDK9CDK1CCNE1CCNB1
SCHEMBL31707903 0.84 CLK1 (0.56) CDK2CDK9CDK1CCNE1CCNB1
Hydrochloric Acid SCHEMBL31707881 0.83 CLK1 (0.55) CDK2CDK9CDK1CCNE1CCNB1
SCHEMBL13057359 0.82 CDK2 (0.61) CDK2CDK9CDK1CCNE1CCNB1
SCHEMBL13057358 0.82 CDK2 (0.61) CDK2CDK9CDK1CCNA2CCNA1
SCHEMBL31629631 0.81 CDK2 (0.47) CDK2CDK9CDK1CCNE1CCNB1
SCHEMBL31629533 0.81 CDK2 (0.47) CDK2CDK9CDK1CCNE1CCNB1
SCHEMBL31707857 0.81 CDK2 (0.45) CDK2CDK9CDK1CCNE1CCNB1
Hydrochloric Acid SCHEMBL31707882 0.80 CDK2 (0.46) CDK2CDK9CDK1CCNE1CCNB1
SCHEMBL31707910 0.80 CDK2 (0.44) CDK2CDK9CDK1CCNE1CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8592581-B2 Trisubstituted purine derivatives CYCLACEL LIMITED (GB) 2013-11-26 US disclosed
CN-101679434-B 2, 6, 9-substituted purine derivatives having anti proliferative properties CYCLACEL LTD 2013-09-25 CN disclosed
EP-2139893-B1 2,6,9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTIPROLIFERATIVE PROPERTIES CYCLACEL LTD (GB) 2013-06-19 EP disclosed
US-20100093769-A1 COMPOUNDS CYCLACEL LIMITED (GB) 2010-04-15 US disclosed
US-20100093769-A1 COMPOUNDS CYCLACEL LIMITED (GB) 2010-04-15 US disclosed
US-20100093769-A1 COMPOUNDS CYCLACEL LIMITED (GB) 2010-04-15 US disclosed
CN-101679434-A Has 2,6 of anti proliferative properties, the purine derivative that 9-replaces CYCLACEL LTD 2010-03-24 CN disclosed
EP-2139893-A2 2,6,9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTIPROLIFERATIVE PROPERTIES Cyclacel Limited (GB) 2010-01-06 EP disclosed
WO-2008122767-A2 2, 6, 9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTI PROLIFERATIVE PROPERTIES CYCLACEL LIMITED (GB) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093769-A1 COMPOUNDS CCR9, NPY1R, BCL9 CDK2 1751/4885CDK9 57/4885CDK1 512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.